Landing
Vision Via Sound for the Blind: Can a Silicon Valley Veteran Deliver the Solution to a $2B NDIS Problem?
Serial entrepreneur Robert Yearsley is trading pixels for perception with ARIA Research, a Sydney-based deep-tech company using “augmented reality in audio” to help the blind perceive the world. By bypassing traditional bionics in favour of real-time 3D soundscapes, ARIA is tackling a multi-billion dollar unmet need in the global disability sector and redefining what it means to “see” without eyesight.
Private Credit Is No Longer Just a Defensive Play. Here Is What Investors Actually Want.
Private credit is no longer just a defensive allocation. Based on our 2026 Investor Survey, the largest segment of investors (44%) now wants hybrid structures that combine yield with equity optionality, demanding that fund managers rethink how credit products are structured, positioned, and sold.
Where Capital Is Flowing in 2026: What Active Investors Told Us About the Sectors That Matter
Every year, we survey our investor network. Not to confirm what we already think, but to understand what is actually driving capital allocation decisions across the sophisticated investor community. This year, the results were striking. Not because they were surprising, but because of how precisely they align with the macro research now emerging from some […]
Every Breath Matters: A Melbourne Startup Solving a Long-Standing Clinical Need in Neonatal Care
A Forbes 30 Under 30 team has developed Ventora Medical, a company solving the critical “blind spot” in neonatal care. By embedding a high-precision sensor technology into enteral feeding tubes , their Airway Pressure Monitor provides real-time data, significantly reducing the 40% failure rate of non-invasive breathing support for premature babies and getting families home sooner.
Targeting the Untouchable: The High-Stakes Race to Outsmart ‘Invisible’ Tumors
Percheron Therapeutics is developing the drug HMBD-002 to target the VISTA protein, aiming to make previously “invisible” cancers visible to the immune system. The company is preparing for its critical Phase 2 human trials in 2026 after successful Phase 1 results showed tumor shrinkage.
The “Anti-Botox” Breakthrough: How a Rural Doctor is Using Tetanus to Help the World Breathe
In the sweltering heat of a rural hospital in Northern India, a young medical student named Tony Sasse witnessed something most Western doctors only read about in textbooks: the terrifying, raw power of tetanus. He watched patients struggle with “lockjaw,” their muscles frozen in a state of hyper-active, agonising contraction. Most saw a deadly disease. […]
Solving Myopia: From the Playground to the Global Stage
For John Nguyen, the moment of clarity did not happen behind a phoropter in a darkened consulting room. It happened at home, watching the daily struggle between screen time and sunshine that defines modern parenting. As an optometrist and founder of Luxi Health, Nguyen knows the clinical data well. He understands that the world is […]
The “Screen Time” Pandemic: Why the World’s Eyeballs are Getting Too Long
With nearly half the world projected to be myopic by 2050, Eyerising International is pioneering a “disease-modifying” solution using low-level red light therapy. The Australian MedTech firm is currently raising $5 million to fund its global expansion and entry into the massive adult treatment market.
Forget antibiotics: Why the next big medical breakthrough is a beam of light
Lindo Life Science, founded by Robert Gangi, is changing the battle against antimicrobial resistance (AMR) with the Lindo Tube, which uses occupant-safe antimicrobial blue light to shatter 99.9% of bacteria. This breakthrough prevents Ventilator-Associated Pneumonia (VAP), a secondary infection affecting nearly one in four intubated patients, and has been validated by a collaboration with the Mayo Clinic.
Backed By Leading Investment Groups and Family Offices
